Toripalimab plus concurrent chemoradiotherapy for recurrent nasopharyngeal carcinoma: A single‐arm, phase 2 clinical trial
Toripalimab plus CCRT demonstrates antitumor efficacy in rNPC. The observed 22.5% rate of fatal epistaxis indicates that its potential benefits must be carefully weighed against this serious treatment-related risk.
Authors
- Fang Su (ORCID: https://orcid.org/0000-0002-6319-5103)
- Chunmi Wei
- Yumei Qin
- Zhehao Xiao
- Junbao Wei (ORCID: https://orcid.org/0000-0002-3716-5496)
- Y Liu
- Kaiguo Li (ORCID: https://orcid.org/0000-0003-2073-5816)
- Binbin Yu
- Fanyan Zeng
- Hejing Huang
- Ye Li
- Jingni Wei
- Youqin Du
- Zhongguo Liang
- Shiting Huang
- Song Qu
- Yanlin Mo
- Ying Guan
Institutions
- Guangxi Medical University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1002/cncr.70257
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Junshi Biosciences